El-Madani M - Search Results

1

Clinical efficacy of the optimal biological dose in early-phase trials of anti-cancer targeted therapies.

Corbaux P, El-Madani M, Tod M, Péron J, Maillet D, Lopez J, Freyer G, You B. Corbaux P, et al. Among authors: el madani m. Eur J Cancer. 2019 Oct;120:40-46. doi: 10.1016/j.ejca.2019.08.002. Epub 2019 Aug 31. Eur J Cancer. 2019. PMID: 31479946 Review.

2

Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.

El-Madani M, Hénin E, Lefort T, Tod M, Freyer G, Cassier P, Valette PJ, Rodriguez-Lafrasse C, Berger F, Guitton J, Lachuer J, Slimane K, Barrois C, You B. El-Madani M, et al. Future Oncol. 2015;11(10):1511-8. doi: 10.2217/fon.15.49. Future Oncol. 2015. PMID: 25963428 Clinical Trial.

3

EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.

El-Madani M, Colomban O, Tod M, Maillet D, Peron J, Rodriguez-Lafrasse C, Badary OA, Valette PJ, Lefort T, Cassier P, El-Shenawy SM, El-Demerdash E, Hommel-Fontaine J, Guitton J, Gagnieu MC, Ibrahim BM, Barrois C, Freyer G, You B. El-Madani M, et al. Future Oncol. 2017 Apr;13(8):679-693. doi: 10.2217/fon-2016-0357. Epub 2017 Jan 12. Future Oncol. 2017. PMID: 28076966 Clinical Trial.

4

Squalenoyl siRNA PMP22 nanoparticles are effective in treating mouse models of Charcot-Marie-Tooth disease type 1 A.

Boutary S, Caillaud M, El Madani M, Vallat JM, Loisel-Duwattez J, Rouyer A, Richard L, Gracia C, Urbinati G, Desmaële D, Echaniz-Laguna A, Adams D, Couvreur P, Schumacher M, Massaad C, Massaad-Massade L. Boutary S, et al. Among authors: el madani m. Commun Biol. 2021 Mar 9;4(1):317. doi: 10.1038/s42003-021-01839-2. Commun Biol. 2021. PMID: 33750896 Free PMC article.

5

Small interfering RNA from the lab discovery to patients' recovery.

Caillaud M, El Madani M, Massaad-Massade L. Caillaud M, et al. Among authors: el madani m. J Control Release. 2020 May 10;321:616-628. doi: 10.1016/j.jconrel.2020.02.032. Epub 2020 Feb 19. J Control Release. 2020. PMID: 32087301 Review.

6

Ferulic acid nanoemulsion as a promising anti-ulcer tool: in vitro and in vivo assessment.

Abd-Allah H, Abdel Jaleel GA, Hassan A, El Madani M, Nasr M. Abd-Allah H, et al. Among authors: el madani m. Drug Dev Ind Pharm. 2024 Apr 13:1-10. doi: 10.1080/03639045.2024.2341786. Online ahead of print. Drug Dev Ind Pharm. 2024. PMID: 38602337

7

Gastroprotective Chitosan Nanoparticles Loaded with Oleuropein: An In Vivo Proof of Concept.

Abd-Allah H, Youshia J, Abdel Jaleel GA, Hassan A, El Madani M, Nasr M. Abd-Allah H, et al. Among authors: el madani m. Pharmaceutics. 2024 Jan 22;16(1):153. doi: 10.3390/pharmaceutics16010153. Pharmaceutics. 2024. PMID: 38276520 Free PMC article.

8

Abiotic degradation of imazethapyr in aqueous solution.

Elazzouzi M, Mekkaoui M, Zaza S, El Madani M, Zrineh A, Chovelon JM. Elazzouzi M, et al. Among authors: el madani m. J Environ Sci Health B. 2002 Sep;37(5):445-51. doi: 10.1081/PFC-120014874. J Environ Sci Health B. 2002. PMID: 12369761

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page